Gilead Sciences Inc. placed another big bet in fibrosis, inking a preclinical deal with Scholar Rock Holding Corp. that includes $80 million up front – $50 million in cash and $30 million in Scholar Rock common shares – along with a one-time milestone payment of $25 million when certain preclinical studies are completed.